Pantolarin Injection (Pantoprazole Sodium Sesquihydrate)

Adult dosage

If oral administration of pantoprazole is not appropriate, dissolve 10 mL of saline injection in each vial of this medicine (equivalent to 40 mg of pantoprazole) and administer by direct intravenous injection, or mix this solution with 100 mL of saline injection or 5% dextrose solution and administer intravenously over 2∼15 minutes. As soon as oral administration becomes possible, discontinue intravenous pantoprazole and replace it with oral pantoprazole 40 mg. 1. Duodenal ulcer, gastric ulcer, moderate to severe reflux esophagitis Administer 1 vial of this medicine (equivalent to 40 mg of pantoprazole) intravenously once daily. 2. Zollinger-Ellison syndrome and other pathological hypersecretory conditions - Start with an initial dose of 80 mg per day, then increase or decrease the dose according to measurements of gastric acid secretion. - For doses of 80 mg or more, administer in 2 divided doses per day. - Temporary increases to 160 mg or more are possible, but should be used only for as long as necessary to achieve adequate acid control. - When rapid acid control is required, an initial dose of 2 × 80 mg reduced acid output to the target range (< 10 mEq/h) within one hour in most patients. &#9711; In patients with severe hepatic impairment, the daily dose should be reduced to 20 mg of pantoprazole. &#9711; In elderly patients or patients with renal impairment, the daily dose should not exceed 40 mg of pantoprazole.

This medication should not be administered to certain patients. Patients who have had allergic reactions to this medication, its ingredients, or benzimidazole derivatives may experience serious allergic symptoms such as anaphylaxis, angioedema, or bronchospasm, and should not use it. Additionally, patients taking atazanavir, nelfinavir, or rilpivirine should not be administered this medication due to interactions. This medication may cause various side effects. Commonly reported symptoms include abdominal pain, diarrhea, constipation, abdominal distension, indigestion, nausea, vomiting, dry mouth, rhinitis, injection site reactions, fever, peripheral edema, headache, dizziness, insomnia, etc. Rarely, liver damage, blood abnormalities, serious skin reactions, muscle problems, psychiatric symptoms, and kidney issues may occur; if any abnormal symptoms arise, consult a healthcare professional immediately. Regular monitoring is required for prolonged use of this medication. Especially if administered for over one year, liver function tests and magnesium levels should be checked periodically. This medication is not used for mild indigestion, and further examination is needed if symptoms persist. Patients with severe liver impairment should reduce the dosage; if liver enzyme levels rise, the medication should be discontinued. Caution is advised as prolonged high-dose administration may increase the risk of bone fractures. This medication may cause hypomagnesemia; therefore, patients taking it for a long time or concurrently with related medications should routinely monitor their magnesium levels and supplement if necessary. Since this medication inhibits gastric acid secretion, it may slightly increase the risk of bacterial infections in the stomach; hence, it is important to report persistent diarrhea to a healthcare provider. Dizziness or vision disturbances may occur, so caution is needed when driving or operating machinery. This medication may interact with other drugs metabolized in the liver; therefore, inform healthcare professionals of any other medications being taken. Particularly, caution is needed as this medication may interact with antiviral agents, anticoagulants, immunosuppressants, etc. It should not be administered during the first three months of pregnancy; it should be used during pregnancy only if the benefits outweigh the risks. It is advisable for breastfeeding women to avoid taking this medication. There is insufficient experience with administration in children or adolescents under 18 years; therefore, it is not used in this age group. No specific symptoms have been reported for overdose, but if any abnormal symptoms occur, immediate treatment should be sought. This medication must be properly diluted before use, and the prepared solution should be used within 12 hours. Store in a dark container to protect from light, and do not use products that are discolored or cloudy. In animal studies, some potential for tumorigenesis has been observed; however, the impact on humans is unclear. Therefore, when using this medication, it is important to adhere to the doctor's instructions for the minimum dosage and appropriate duration of use.

Anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute interstitial nephritis, urticaria, agranulocytosis, leukopenia, thrombocytopenia, pancytopenia, upper abdominal pain, diarrhea, constipation, abdominal distension, dyspepsia, gastric polyps, nausea, vomiting, dry mouth, rhinitis, injection site reaction, thrombophlebitis at the injection site, fever, peripheral edema, pyrexia, elevated bilirubin, liver failure, jaundice, hepatocellular damage, elevated liver enzymes, arthralgia, myalgia, rhabdomyolysis, bone fracture, headache, dizziness, visual disturbances, taste disturbances, insomnia, sleep disorders, depression, hallucinations, disorientation, confusion, interstitial nephritis, pruritus, skin erythema, Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, photosensitivity reaction, gynecomastia, hyperlipidemia, increased lipids, weight change, hyponatremia, hypomagnesemia, elevated CK, systemic lupus erythematosus, cutaneous lupus erythematosus, pancreatitis, confusion, decreased activity, speech disorder, increased salivation, vertigo, tinnitus, hypocalcemia, hypokalemia, Clostridium difficile-associated diarrhea, paresthesia, DRESS syndrome, microscopic colitis

This medication is sensitive to light and should be stored in a dark container. Additionally, it is important to store it at a cool temperature below 25 degrees Celsius to maintain its effectiveness.

Appearance

This medication is a white porous solid or powder contained in a colorless transparent vial, and it is an injectable solution that is to be dissolved prior to use.

Package unit

1 vial, 10 vials